Plain-English translation of NCT05151809 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Primary Biliary Cholangitis research guide →Researchers are building a nationwide database of patients with primary biliary cholangitis (a disease where your immune system damages the bile ducts in your liver) to understand why some people respond well to ursodeoxycholic acid (UDCA), the standard treatment, while others don't. By collecting medical information and blood samples from thousands of patients across Italy, scientists hope to discover genetic and biological clues that explain why certain groups—especially younger patients—struggle with this medication and what options might work better for them.
About 20 to 30 percent of patients with primary biliary cholangitis don't benefit from the current standard treatment, putting them at risk for serious liver damage and the need for a transplant. By studying the genes, proteins, and metabolism of many patients, researchers hope to identify who is at highest risk and develop new, personalized treatment approaches.
You likely qualify if…
You likely don't qualify if…
If you join, you'll share your medical records and history with the research team, and you may be asked to donate a blood sample that will be stored in a research biobank for current and future studies. The study is being conducted across about 60 centers in Italy, so you would likely work with a clinic or hospital near you. This is an observational study, meaning researchers will track your health information over time but won't ask you to take any new medications—they're simply learning from your existing care.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Italy